Lansoprazole Capsule, Delayed Release
Product Images NDC 70700-263

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 70700-263). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle-label-15mg.jpg (Bottle Label 15mg)

This is a prescription medication called Lansoprazole, and the package contains 30 delayed-release capsules, each capsule containing 15mg of Lansoprazole. It is used to treat stomach and digestive problems. The usual dosage should be determined by a doctor or pharmacist. The medication must be kept out of the reach of children and stored at a temperature between 20 to 25°C. It should not be used if the seal over the bottle opening is broken or missing. This medication is made in Spain and dispensed in a tight container. For further information regarding usage, refer to the package insert.*

FDA Label Image

Bottle-label-30mg.jpg (Bottle Label 30mg)

This is a description of Lansoprazole Delayed-Release Capsules. Each bottle has 30 capsules and is only available with a prescription. The usual dosage information can be found in the package insert. It is important to keep this medication out of reach of children. The manufacturer for this medication is Xiromed LLC, located in Florham Park, NJ. The medication is made in Spain and should be stored at a temperature between 20-25°C (68-77°F). If the seal over the bottle is broken or missing, do not accept the medication. Unfortunately, there's no information about the medication's usage or indications.*

FDA Label Image

Figure-1.jpg (Figure 1)

This is a chart that shows the mean severity of day heartburn by study day for evaluable patients, categorized as severe, moderate, mild, or none (rated from 3 to 0). The chart includes three treatment options: placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD. There are a total of 25 study days and the days from the start of treatment are also mentioned.*

FDA Label Image

Figure-2.jpg (Figure 2)

This document presents data on the mean severity of night heartburn for evaluable patients recorded on different study days, where severity was evaluated using a scale of 0 to 3 (where 3 represents severe heartburn). The data shows the mean severity of night heartburn experienced by patients who received a placebo, 15mg daily dose of lansoprazole, or 30mg daily dose of lansoprazole. The results were measured starting from the first day of treatment, up to day 18. There is also a chart indicating the percentage of patients who reported a particular degree of severity, grouped by study day.*

FDA Label Image

Formula-structure.jpg (Image 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.